Web Analytics Made Easy - Statcounter

top of page

Multiple Myeloma Clinical Trials @ Mount Sinai, NY
Currently Recruiting

Multiple Myeloma Clinical Trials at Mount Sinai NY

1/24

RRMM

NCT05347485: Phase 2: A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release

2022 - (R) NCT05347485

Phase 2: A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release

NCT05000450: Phase 1/2: Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell RRMM

2021 - (R) NCT05000450

Phase 1/2: Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell RRMM

NCT04975399: Phase 1: Study to Evaluate the Safety and Tolerability of CC-92328 in Participants RRMM

2021 - (R) NCT04975399

Phase 1: Study to Evaluate the Safety and Tolerability of CC-92328 in Participants RRMM

NCT04756726: Phase 1/2: CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma

2021 - (R) NCT04756726

Phase 1/2: CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma

NCT04394650: Phase 1 - CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in RRMM

2020 - (R) NCT04394650

Phase 1 - CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in RRMM

NCT04093596: Phase 1 - ALLO-715 BCMA Allogenic CAR T Cells in relapsed Multiple Myeloma (UNIVERSAL)

2020 - (R) NCT04093596

Phase 1 - ALLO-715 BCMA Allogenic CAR T Cells in relapsed Multiple Myeloma (UNIVERSAL)

NCT04133636: Phase 2 - Study of JNJ-68284528, CAR-T Therapy Directed Against BCMA in MM -CARTITUDE-2

2019 - (R) NCT04133636

Phase 2 - Study of JNJ-68284528, CAR-T Therapy Directed Against BCMA in MM -CARTITUDE-2

NCT04108195: Phase 1b - Subcutaneous Dara With Bispecific T Cell Redirection Antibodies - TRIMM-2

2019 - (R) NCT04108195

Phase 1b - Subcutaneous Dara With Bispecific T Cell Redirection Antibodies - TRIMM-2

NCT04036461: Phase 1 - A Study of CC-99712, a BCMA Antibody-Drug Conjugate in relapsed MM

2019 - (R) NCT04036461

Phase 1 - A Study of CC-99712, a BCMA Antibody-Drug Conjugate in relapsed MM

NDMM

NCT04052880 : Phase 2 - SubQ Dara + Dose-Atten. Bortezomib, Lenalidomide, Dex New MM >70 years

2019 - (R) NCT04052880

Phase 2 - SubQ Dara + Dose-Atten. Bortezomib, Lenalidomide, Dex New MM >70 years

NCT03901963: Phase 3 - Dara + Len vs Len as Maint. in New Myeloma +MRD after frontline ASCT (AURIGA)

2019 - (R) NCT03901963

Phase 3 - Dara + Len vs Len as Maint. in New Myeloma +MRD after frontline ASCT (AURIGA)

NCT04196491: Phase 1 - Evaluate the Safety of bb2121 in High Risk, New Myeloma (NDMM) (KarMMa-4)

2019 - (Active) NCT04196491

Phase 1 - Evaluate the Safety of bb2121 in High Risk, New Myeloma (NDMM) (KarMMa-4)

United States - Myeloma Clinical Trials | MCT Index (themyelomaclinicaltrials.com)

bottom of page